Nivolumab
BMS
[]
 acknowledge all the merits of this study but would be cautious in interpreting results given small ph2 study with an inherently large false positivity rate that may or may not pass the test of confirmatory ph3 trial for this population. 
Medical Oncologist & Hematologist • @AKUGlobal & @PennStHershey Alum • Adjunct Clinical Associate Professor @KhalifaUni • LGP ESMO Asia 22 • SSMC/Mayo Clinic •